Tag Archives: Medidata

13Jul/21

Dassault Systèmes Articulates Interconnected Life-Science Vision

Dassault Systèmes 2021 Analyst Conference Event Brief

By: Sandra K. Rodriguez, Senior Industry Analyst and Daniel R. Matlis, President

Dassault Systèmes continued to articulate its interconnected Life-Science vision at the 2021 Analyst conference.

“In the experience economy, business science and innovation are all about relationships,” said Bernard Charlès, Vice Chairman, Chief Executive Officer at Dassault Systèmes. “The real phenomenon of the platform is about building an interconnected continuous interactive loop with your value chain from design to user experience,” he added.

“We are not talking about upstream and downstream applications anymore, it’s a continuous flow of imagine, create, produce, advocate, value and use,” said Charlès.

While Axendia does not believe in force ranking vendors because there is no BEST (see: Who is the Best Technology Vendor?), Dassault Systèmes executives were the first to articulate their avant-garde vision to support the Life-Science value network from end to end.  This vision is backed by an impressive offering portfolio aimed at providing an interconnected and continuous interactive platform that supports the Life-Science value network from end to end. 

Continue reading
25Jul/19

Medidata: The Missing Link in Dassault Systèmes Powerful Portfolio to Support the Life-Science Industry

Dassault Systèmes Analyst Conference Brief 2019

By: Sandra K. Rodriguez, Market Analyst

The news out of this years’ Dassault Systèmes Analyst Conference was huge: a $5.8 Billion merger offer with clinical data giant, Medidata.  We received the news while traveling from our hotel to the Dassault Systèmes headquarters, nestled in Vélizy-Villacoublay, France.  Aside from the size of the deal – the largest in the history of Dassault Systèmes – Medidata was the missing link in its powerful portfolio to support the Life-Science industry.

Bernard Charlès, CEO and vice-chairman of the board of directors at Dassault Systèmes, opened the two-day meeting with, “To do ‘smart’ anything, you need to know the environment.  The platform phenomenon is not an IT topic… it’s a new way for companies to work.”  Dassault Systèmes now has 250,000 customers, with 25 million users in 140 countries.  The 3DEXPERIENCE platform currently consists of 11 brands/applications that support the ability for people and businesses to develop, collaborate and build products and services in both the virtual and real worlds.

Dassault Systèmes considers itself a Scientific company, first and foremost.   The Industry Renaissance theme of this years’ conference was explained in simple terms by Morgan Zimmermann, CEO for NETVIBES-EXALEAD (the Dassault Systèmes solution for turning large amounts of information into intelligence).  “Think of Renaissance as the new book. The book changed how we distributed knowledge; Industry Renaissance for Dassault Systèmes is the usage of experience as a new way to distribute knowledge and know-how” explained Zimmermann.

The 3DEXPERIENCE Platform offers both people and businesses, virtual universes to imagine, develop and collaborate using innovative solutions.

Life is the New Work Bench

Mentioned earlier in this brief, Medidata was the missing link in the Dassault Systèmes solution platform to support end-to-end product development in the Life-Sciences.  “Pharmaceutical and Biotech companies require roughly ten to twelve years in the R&D phase to bring a drug or therapy to market” explained Claire Biot, Ph.D., VP of Life Sciences Industry at Dassault Systèmes.  Therefore, shifting that timeline left early on in the clinical trial phase of a product adds significant value to Life-Sciences companies.

Image Courtesy of Dassault Systèmes

Image Courtesy of Dassault Systèmes – Claire Bisot.

Clinical trials are necessary to prove the safety and efficacy of a drug on not only a patient population, but the medical condition itself.

Download and read the entire Briefing Note.